Longitudinal invariance of the positive and negative syndrome scale negative dimension in antipsychotic naive first-episode schizophrenia

Autor(es):Mostrar menos -

Kagan, Simao ^{[1, 2]} ; Cogo-Moreira, Hugo ^[1] ; Barbosa, Matheus Ghossain ^[1] ; Cavalcante, Daniel ^{[1, 3]} ; Shinji, Andre ^{[1, 3]} ; Noto, Mariane ^[3] ; Haguiara, Bernardo ^{[1, 2]} ; Cordeiro, Quirino ^[1] ; Belangeiro, Sintia ^{[4, 1]} ; Bressan, Rodrigo A. ^{[1, 2, 5]} ; Noto, Cristiano ^{[1, 2, 3, 5]} ; Gadelha, Ary ^{[1, 2, 3, 5]}

Afiliação do(s) autor(es)

^[1] Fed Univ Sao Paulo EPM UNIFESP, Dept Psychiat, Lab Integrat Neurosci LiNC, Sao Paulo - Brazil

^[2] Fed Univ Sao Paulo UNIFESP, Dept Psychiat, Schizophrenia Program PROESQ, Sao Paulo - Brazil

^[3] Fed Univ Sao Paulo UNIFESP, Dept Psychiat, Early Psychosis Grp GAPI, Sao Paulo - Brazil

^[4] Fed Univ Sao Paulo Unifesp, Dept Morphol & Genet, Sao Paulo - Brazil

^[5] Fed Univ Sao Paulo UNIFESP, Ctr Res & Innovat Prevent Mental Disorders & Drug, Dept Psychiat, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: EARLY INTERVENTION IN PSYCHIATRY; JUL 2021.
• Citações Web of Science: 0

Resumo

Aim Construct stability over time is required for reliable inference, but evidence regarding the longitudinal invariance of negative symptoms is still limited. Thus, we examined the longitudinal invariance of the negative dimension using the positive and negative syndrome scale (PANSS) in an antipsychotic-naive first-episode schizophrenia sample at baseline and after 10 weeks. Methods Our study was conducted at a specialized early intervention service. PANSS ratings were analysed for 138 patients, and two different models were specified and tested: a unidimensional and a two-correlated factor solution. Results The unidimensional model fulfilled criteria for longitudinal invariance, whilst the two-correlated did not. Conclusion Our study provides support for the PANSS negative unidimensional model use to evaluate negative symptoms' longitudinal change following first-episode schizophrenia. (AU)

• Processo FAPESP: 14/07280-1 - Busca por marcadores genéticos de risco, de progressão e de reposta ao tratamento na esquizofrenia
• Beneficiário: Síntia Iole Nogueira Belangero
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 17/25016-8 - Investigação da resposta ao tratamento da esquizofrenia com risperidona: estudo farmacogenético em uma coorte de pacientes em primeiro episódio psicótico
• Beneficiário: Síntia Iole Nogueira Belangero
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 10/08968-6 - Investigação de marcadores genéticos e epigenéticos: uma abordagem translacional para o tratamento de esquizofrenia
• Beneficiário: Síntia Iole Nogueira Belangero
• Modalidade de apoio: Auxílio à Pesquisa - Regular